CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
Recruiting · NCT06096675 · Interventional (participants receive a specific treatment) · Lead sponsor: Wake Forest University Health Sciences
View the official record on ClinicalTrials.gov →Interventions studied
• Cardiac Rehabilitation
What this trial is about
Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age \> 18
- New York Heart Association (NYHA) Class I-III Heart Failure
- Able to Exercise
- On stable treatment for their cardiac amyloidosis or under active surveillance
- Life expectancy of at least 6 months
- Ability to understand and the willingness to sign a written informed consent document in English, and the willingness/ability to comply with the protocol activities
- Participant must be able and willing to follow the cardiac rehabilitation activities
Exclusion criteria
- Inability to provide informed consent
- Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks
- NYHA Class IV Heart Failure
- Pulmonary disease requiring home oxygen
- Gait instability or history of prior falls
- In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.
Where it is running
1 location listed across 1 US state.
- Sanger Heart and Vascular Institute - Charlotte, North Carolina, United States